Hold Rating on XPeng ADR Amid MONA M03 Launch Uncertainty and Competitive Pricing Challenges
Hold Rating on BeiGene Amid Mixed Drug Performance and Strong Pipeline Potential
BeiGene's Strong Financial and Clinical Prospects Solidify Buy Rating
Buy Rating Affirmed for Zai Lab on Strong Financials and Promising Pipeline Developments
BeiGene Analyst Ratings
BeiGene's Brukinsa Drives Strong Growth and Justifies Buy Rating
Buy Rating for BeiGene Backed by Brukinsa's Market Growth and Strong Financial Outlook
Zai Lab Analyst Ratings
Bank of America Securities Sticks to Their Buy Rating for Zai Lab (ZLAB)
Nomura Adjusts Price Target on Kingsoft Cloud to $2.30 From $3, Maintains Neutral Rating
Nomura Adjusts Yum China Holdings' Price Target to HK$365.82 From HK$455.52, Keeps at Buy
Buy Rating Affirmed for Yum China Holdings Amid Expansion and Strong Market Presence
Yum China Holdings Analyst Ratings
Oppenheimer Sticks to Their Hold Rating for Yum China Holdings (YUMC)
Analysts Offer Insights on Consumer Cyclical Companies: Yum China Holdings (YUMC) and E.l.f. Beauty (ELF)
HUTCHMED (China) Analyst Ratings
Hold Rating on HUTCHMED Amid Promising U.S. Launch and Pending EU Reimbursement Clarity
Alibaba Group Holding Price Target Maintained With a $116.00/Share by Jefferies
Nomura Adjusts BeiGene's Price Target to HK$158.37 From HK$150, Keeps at Buy
Zai Lab Analyst Ratings